Immune checkpoint inhibitor-associated nephritis-treatment standard
Overview
Paper Summary
This review summarizes current knowledge and treatment approaches for immune checkpoint inhibitor (ICI)-associated acute kidney injury (AKI), a side effect of cancer immunotherapy. It focuses on acute tubulointerstitial nephritis (ATIN), the most common form of ICI-AKI, discussing diagnosis, treatment, and outcomes, emphasizing the need for more prospective studies.
Explain Like I'm Five
Some cancer drugs can cause kidney problems as a side effect. Doctors are figuring out how to diagnose and treat these problems, but more research is needed.
Possible Conflicts of Interest
One author (SMH) has received research funding from intramural and Mayo Clinic grants. No specific funding was disclosed for the preparation of this manuscript.
Identified Limitations
Rating Explanation
This is a comprehensive review of an important topic in onco-nephrology. It summarizes the current understanding of ICI-AKI and highlights key areas for future research. While it relies on retrospective studies, this is a limitation of the current evidence base. The authors acknowledge this weakness and call for more prospective research. Potential COI noted but seems minimal.
Good to know
This is the Starter analysis. Paperzilla Pro fact-checks every citation, researches author backgrounds and funding sources, and uses advanced AI reasoning for more thorough insights.
Explore Pro →